Literature DB >> 33900518

MicroRNA-93 Blocks Signal Transducers and Activator of Transcription 3 to Reduce Neuronal Damage in Parkinson's Disease.

Xiufeng Wang1, Zhijun Liu1, Fang Wang2.   

Abstract

MicroRNA-93 (miR-93) is an oncogene that promotes tumor growth and angiogenesis. However, its role in Parkinson's disease (PD) remains unknown. This study aimed at investigating the role of miR-93 in PD and the molecular mechanisms involved. 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced PD mouse model and lipopolysaccharide (LPS)-exposed BV2 cells were constructed. Real-time quantitative PCR was used to detect the mRNA expression of miR-93, iNOS, IL-6, IL-10, TNF-α and TGF-β1. Bioinformatics analysis and luciferase reporter assay were used to predict and confirm the interaction between miR-93 and STAT3. Flow cytometry was used to detect cell apoptosis. Western blotting was used to detect the protein expression of STAT3. Immunohistochemistry was used to analyze the Iba1-positive and TH positive cells. It was found that the expression of miR-93 was down-regulated in LPS-exposed BV2 cells. Overexpression of miR-93 inhibited the expression of iNOS, IL-6 and TNF-α, while enhanced the expression of TGF-β1 and IL-10. The expression of transcriptional activator 3 (STAT3) was found to be up-regulated in LPS-exposed BV2 cells. Knockdown of STAT3 inhibited the expression of iNOS, IL-6 and TNF-α, while enhanced the expression of TGF-β1 and IL-10. Moreover, STAT3 was found to be a direct target of miR-93, and miR-93 overexpression inhibited the expression of STAT3. Furthermore, both miR-93 overexpression and STAT3 knockdown reduced LPS-induced BV2 cell apoptosis, whereas STAT3 overexpression eliminated the inhibitory effect of miR-93 on LPS-induced BV2 cell apoptosis. In addition, miR-93 overexpression inhibited MPTP-induced STAT3 expression, microglial activation and inflammatory reaction and reduced the loss of tyrosine hydroxylase in the substantia nigra of mice. In conclusion, we demonstrate that miR-93 may be involved in PD by regulating the expression of STAT3.

Entities:  

Keywords:  Neuroinflammatory reaction; PD; STAT3; miR-93

Year:  2021        PMID: 33900518     DOI: 10.1007/s11064-021-03333-x

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  3 in total

1.  MicroRNA-7 inhibits neuronal apoptosis in a cellular Parkinson's disease model by targeting Bax and Sirt2.

Authors:  Shize Li; Xuecheng Lv; Kaihua Zhai; Ruyan Xu; Yong Zhang; Songyao Zhao; Xiaoming Qin; Liujie Yin; Jiyu Lou
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

2.  MiR-93 blocks STAT3 to alleviate hepatic injury after ischemia-reperfusion.

Authors:  L Xiong; K-H Yu; S-Q Zhen
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-08       Impact factor: 3.507

3.  Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations.

Authors:  L S Forno; L E DeLanney; I Irwin; J W Langston
Journal:  Adv Neurol       Date:  1993
  3 in total
  4 in total

1.  Echinacoside Protects Dopaminergic Neurons Through Regulating IL-6/JAK2/STAT3 Pathway in Parkinson's Disease Model.

Authors:  Xueping Yang; Qingyun Yv; Fanlong Ye; Sheng Chen; Zhang He; Wenwei Li; Fang Dong
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

Review 2.  Crosstalk between regulatory non-coding RNAs and oxidative stress in Parkinson's disease.

Authors:  Hantao Zhang; Xiaoyan Liu; Yi Liu; Junlin Liu; Xun Gong; Gang Li; Min Tang
Journal:  Front Aging Neurosci       Date:  2022-08-09       Impact factor: 5.702

Review 3.  The Role of Non-Coding RNAs in the Pathogenesis of Parkinson's Disease: Recent Advancement.

Authors:  Hanwen Zhang; Longping Yao; Zijian Zheng; Sumeyye Koc; Guohui Lu
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-30

4.  Regulation of Parkinson's disease-associated genes by Pumilio proteins and microRNAs in SH-SY5Y neuronal cells.

Authors:  Lisa J Snoderly-Foster; Wendy M Olivas
Journal:  PLoS One       Date:  2022-09-29       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.